The Global Ulcerative Colitis Market was valued at USD 5.44 billion in 2020 and is projected to grow at a CAGR of 6.7%, to reach USD 7.52 billion by 2025 during the forecast period 2020 to 2025.
Ulcerative colitis is an inflammatory bowel disease that can cause ulcers in larger intestine, irritation, inflammation. The major cause for the disease is a dysfunctional immune system resulting in failure of white blood cells, due to ulcerative colitis the white blood cells start attacking the lining of the colon leading to severe inflammation and ulcers. Ulcerative colitis does not have a complete cure but the disease can be controlled by taking proper treatments at regular intervals.
The major factor that is fueling the growth of the global ulcerative colitis market is the increasing incidence of ulcerative colitis due to the increasing population across the world. Factors such as commercialization and influx of investments in healthcare are leading to the development of novel treatment procedures which are fueling the growth of the ulcerative colitis market. Also, the availability of advanced treatments for ulcerative colitis owing to technological advancements and increasing patient pool in need of treatment are key catalyzing factors that are responsible for the growth of the ulcerative colitis market. Other responsible factors for the growth of the market are increasing demand for symptomatic therapeutics, the influx of enhancing drugs into the market, increasing adoption of steroids and biologics to treat ulcerative colitis.
The major challenge which is restricting the growth of the ulcerative colitis market is the stringent approval process of biosimilars. Unfavorable rules and policies and varying conditions in different countries are also limiting the growth of the ulcerative colitis market. Patent expiration of blockbuster drugs is expected to slow down the growth pace of the ulcerative colitis market during the forecast period.
The ulcerative colitis market is growing rapidly and is expected to offer lucrative market opportunities owing to factors such as increasing demand for treatment of ulcerative colitis, lack of medication, personalized therapy and curative therapy for ulcerative colitis. Increasing initiatives on research and developments by public and private organizations in health care are expected to boost the opportunities for stakeholders operating in the ulcerative colitis market.
Recent developments:
IMPACT OF COVID-19 ON ULCERATIVE COLITIS MARKET
In the early years of 2021, the COVID-19 outbreak started to spread around the world, infecting millions of people and prompting large governments around the world to declare it a public health emergency. Many markets have been negatively impacted by the emerging COVID-19 outbreak. UC is a severe inflammatory disease of the large intestine or colon. This condition affects people of all ages. COVID-19 has been found to have a greater risk of adverse effects in patients with ulcerative colitis than in patients with Crohn's disease. Coronavirus disease (COVID-19) risk and results in more in patients with inflammatory bowel disease. Due to this, over the forecast period of 2021 to 2026, the global ulcerative colitis market is expected to grow moderately due to new advances in ulcerative colitis for COVID19 affected people also.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 - 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 – 2025 |
|
Segments Analysed |
By Product, Type, Route of Administration and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
|
Companies Analysed |
Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche, Shire Pharmaceuticals |
This research report on the Global Ulcerative Colitis Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2025.
Ulcerative Colitis Market Analysis - By Product
On the basis of product, Biosimilars hold the largest market share due to their high production in the last decade due to the patent expiration of branded drugs. The monoclonal antibodies segment is the fastest-growing segment due to its effectiveness in curing the disease.
Ulcerative Colitis Market Analysis - By Type
On the basis of type, the Proctosigmoiditis segment is the most common type of ulcerative colitis and hence it holds the major market share.
Ulcerative Colitis Market Analysis - By Route of Administration
Regional Analysis
North America has the biggest share of the ulcerative colitis market. The presence of established key players, as well as the increasing patient pool of UC patients, is the most significant factor driving regional development. Furthermore, the advanced healthcare system is expected to greatly propel the ulcerative colitis market during the forecast period. Johnson & Johnson Services Inc. announced new results from its Phase III UNIFI trial in March 2019, demonstrating that STELARA is beneficial in adults with mild to serious ulcerative colitis.
Europe is in second place due to the government's supportive policies, which have resulted in the growth of the regional ulcerative colitis sector. During the analysis period, the regional demand is expected to be greatly fueled by economic growth and improved healthcare services. Focus on the development of healthcare facilities and the funding given by numerous governments; the APAC region is expected to be the fastest-growing ulcerative colitis sector. Furthermore, emerging countries such as India and China are expected to contribute significantly to the growth of the regional economy.
Due to poor political and economic conditions, the MEA zone is expected to have the smallest ulcerative colitis market share. In addition, a lack of understanding and a poorly developed healthcare system is likely to stifle demand growth.
Top companies leading the Global Ulcerative Colitis Market profiled in this report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche, Shire Pharmaceuticals.
The ulcerative colitis market is comprised of several key companies, such as AbbVie Inc., Merck, Johnson and Johnson, and others. These companies have implemented specific strategic plans, such as mergers, new product launches, acquisitions, and partnerships, to strengthen their market position.
Key happenings in this market in the recent past:
In May 2018, Takeda Pharmaceutical Company Limited and Shire PLC announced that Takeda had reached an agreement on the terms of a proposed offer to acquire all of Shire's outstanding shares and future common shares.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Monoclonal Antibodies
5.1.2.1 Humira
5.1.2.2 Simponi
5.1.2.3 Remicade
5.1.2.4 Entyvio
5.1.3 Biosimilars
5.1.4 Pharmaceuticals
5.1.4.1 Mesalamine
5.1.4.1.1 Asacol HD
5.1.4.1.2 Pentasa
5.1.4.1.3 Lialda
5.1.4.1.4 sfRowasa
5.1.4.2 Balsazide
5.1.4.2.1 Colazal
5.1.4.2.2 Giazo
5.1.4.3 Budesonide
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Proctosigmoiditis
5.2.3 Ulcerative Proctitis
5.2.4 Pancolitis
5.2.5 Left-sided Colitis
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Route of Administration
5.3.1 Introduction
5.3.2 Oral
5.3.3 Injectable
5.3.4 Y-o-Y Growth Analysis, By Route of Administration
5.3.5 Market Attractiveness Analysis, By Route of Administration
5.3.6 Market Share Analysis, By Route of Administration
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Route of Administration
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Route of Administration
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Route of Administration
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline
8.3 Pfizer
8.4 Takeda Pharmaceuticals
8.5 AbbVie
8.6 Johnson and Johnson
8.7 Merck
8.8 Sanofi
8.9 F. Hoffmann-La Roche
8.10 Shire Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
